Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 9;57(5):463.
doi: 10.3390/medicina57050463.

Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)

Sven Otto  1   2 , Suad Aljohani  3 , Riham Fliefel  2   4   5 , Sara Ecke  2 , Oliver Ristow  6 , Egon Burian  7 , Matthias Troeltzsch  2 , Christoph Pautke  2 , Michael Ehrenfeld  2
Affiliations
Review

Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)

Sven Otto et al. Medicina (Kaunas). .

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side effect of antiresorptive, and antiangiogenic drugs commonly used in cancer management. Despite a considerable amount of literature addressing MRONJ, it is still widely accepted that the underlying pathomechanism of MRONJ is unclear. However, several clinical and preclinical studies indicate that infection seems to have a major role in the pathogenesis of MRONJ. Although there is no conclusive evidence for the infection hypothesis yet, available data have shown a robust association between local infection and MRONJ development. This observation is very critical in order to implement policies to reduce the risk of MRONJ in patients under antiresorptive drugs. This critical review was conducted to collect the most reliable evidence regarding the link between local infection and MRONJ pathogenesis.

Keywords: MRONJ; bisphosphonates; denosumab; infection; medication-related osteonecrosis of the jaw; periodontitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Von Moos R., Costa L., Gonzalez-Suarez E., Terpos E., Niepel D., Body J.J. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat. Rev. 2019;76:57–67. doi: 10.1016/j.ctrv.2019.05.003. - DOI - PubMed
    1. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoOaMS American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2007;65:369–376. doi: 10.1016/j.joms.2006.11.003. - DOI - PubMed
    1. Aghaloo T.L., Felsenfeld A.L., Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg. 2010;68:959–963. doi: 10.1016/j.joms.2009.10.010. - DOI - PMC - PubMed
    1. Otto S., Pautke C., van den Wyngaert T., Niepel D., Schiodt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat. Rev. 2018;69:177–187. doi: 10.1016/j.ctrv.2018.06.007. - DOI - PubMed
    1. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O’Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014;72:1938–1956. doi: 10.1016/j.joms.2014.04.031. - DOI - PubMed

MeSH terms

Substances